Keros doses first patient in Phase 2 rinvatercept trial for Duchenne muscular dystrophy
KROS•Keros Therapeutics dosed the first patient in a Phase 2 trial of rinvatercept for Duchenne muscular dystrophy, with early data expected in the first half of 2027.
1. Trial begins
Keros Therapeutics dosed the first patient in a Phase 2 trial of rinvatercept for Duchenne muscular dystrophy. The study is intended to assess whether the treatment can improve outcomes for ambulatory and non-ambulatory patients; early data are expected in the first half of 2027.
